Sichuan Huiyu Pharmaceutical Co., Ltd
13
7
8
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Human Bioequivalence Study of Liposomal Amphotericin B for Injection
Role: lead
Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer
Role: lead
A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation
Role: lead
A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
Role: lead
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
Role: lead
Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors
Role: lead
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
Role: lead
Human Bioequivalence Study of Amphotericin B Liposome for Injection
Role: lead
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Role: lead
Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants
Role: lead
Bioequivalence Study of Iron Sucrose Injection in Healthy Participants
Role: lead
Bioequivalence Study of Iron Sucrose Injection in Healthy Subjects
Role: lead
Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia
Role: lead
All 13 trials loaded